Key Highlights
- Shares are trading down 6.31% intraday to $57.57, from a prior close of $61.45
- Second quarter 2026 Revenue was $3.78 billion, missing the $3.98 billion estimate
- Adjusted EPS of $0.45 beat the $0.40 estimate by 21.62%
- Decline extends a slide that began after the company's cautious 2026 adjusted EBITDA guidance
- Insider selling by company leadership, including CEO Jon Rousseau, added to investor caution
- Institutional buyers like Bank of America and Ausbil Investment Management disclosed increased stakes
- Wall Street's bullish long-term view remains intact, with an average price target of $70.71
Shares Extend Decline From Post-Earnings Slide
BrightSpring Health Services (NASDAQ:BTSG) shares are trading down 6.31% intraday to $57.57, from a prior close of $61.45, extending a slide that began after the company's second quarter results showed shares tumble roughly 18% despite beating estimates on adjusted EPS. Revenue of $3.78 billion missed the $3.98 billion consensus estimate, while adjusted EPS of $0.45 beat the $0.40 estimate by 21.62%.
The continued decline comes as investors focus on cautious full-year 2026 adjusted EBITDA guidance of $820 million to $845 million and deleveraging targets below 2 times rather than the topline beat, with insider selling by company leadership, including Chief Executive Officer Jon Rousseau, adding to investor caution around the stock.
What BrightSpring Health Services Does
BrightSpring Health Services is a Louisville, Kentucky-based home and community-based healthcare services platform founded in 1974, serving over 450,000 customers, clients, and patients daily across all 50 states. The company operates through two primary segments: Pharmacy Solutions and Provider Services, delivering complementary pharmacy and clinical care solutions to complex, chronic, and high-need patient populations covered under Medicare, Medicaid, and commercial insurance.
The company's comprehensive service offerings include specialty pharmacy, home health care, primary care, rehabilitation, behavioral health, hospice, and palliative care, all designed to optimize patient outcomes in lower-cost home and community settings. With approximately 23,500 full-time employees and a market Capitalization of approximately $13.8 billion, BrightSpring went public on the Nasdaq Global Select market in January 2024 and is led by President and Chief Executive Officer Jon Rousseau.
Segment Performance and Balance Sheet
Pharmacy Solutions segment revenue grew 22% year over year to $3.4 billion, up 44% including Amedisys and LHC acquired branches from prior expectations, while Provider Services segment revenue grew 30% to $466 million, up 33% from prior expectations. The company's full-year 2026 revenue guidance was raised to a range of $15.1 billion to $15.425 billion, representing 17% to 19.5% growth, though the cautious adjusted EBITDA and cash-flow-to-EBITDA conversion targets appear to be weighing more heavily on sentiment than the raised revenue outlook.
The company's Balance Sheet strengthened significantly, with Leverage reduced to 2.15 times as of June 30, 2026, down from an adjusted 2.4 times before acquisitions, and the company received Credit rating upgrades from both Moody's and S&P. Institutional buyers including Bank of America and Ausbil Investment Management disclosed increased or new stakes in the company even as insiders sold shares, reflecting a disconnect between Wall Street's bullish long-term view and the stock's sharp post-earnings pullback.
Conclusion
BrightSpring Health Services' continued intraday decline reflects investor focus on cautious profitability and Cash Flow guidance rather than the company's adjusted EPS beat and raised revenue outlook. With leverage improving, credit ratings upgraded, and institutional investors like Bank of America adding to their positions even as insiders sold shares, the disconnect between the stock's sharp pullback and its improving balance sheet fundamentals suggests the market may be overly focused on near-term guidance caution relative to the company's longer-term growth trajectory.






Please wait processing your request...